Canton Strategic Holdings (CNTN) Cash & Equivalents (2020 - 2026)
Canton Strategic Holdings (CNTN) reported Cash & Equivalents of $41.5 million for Q1 2026, up 3760.12% on a YoY basis from $1.1 million in Q1 2025, and up 143.84% quarter-over-quarter from $17.0 million in Q4 2025.
Canton Strategic Holdings (CNTN) Cash & Equivalents (2020 - 2026) Analysis & Trends
Canton Strategic Holdings has reported Cash & Equivalents for 7 years, with the latest figure at $41.5 million in Q1 2026.
- For the quarter ending Q1 2026, Cash & Equivalents rose 3760.12% year-over-year to $41.5 million; the trailing twelve-month figure through Mar 2026 stood at $41.5 million (up 3760.12% YoY), and the FY2025 full-year result was $17.0 million, up 378.53% from the prior year.
- Cash & Equivalents for Q1 2026 stood at $41.5 million, up from $17.0 million in the prior quarter.
- The five-year high for Cash & Equivalents was $41.5 million in Q1 2026, with the low at $1.1 million in Q1 2025.
- Historically, Cash & Equivalents has averaged $8.8 million across 5 years, with a median of $7.6 million in 2022.
- Annual changes were most pronounced in 2022 — Cash & Equivalents surged 149361.29% — and 2025, when it plunged 87.23%.
- Canton Strategic Holdings' Cash & Equivalents stood at $6.5 million in 2022, then surged by 67.96% to $10.9 million in 2023, then slumped by 67.45% to $3.6 million in 2024, then jumped by 378.53% to $17.0 million in 2025, then jumped by 143.84% to $41.5 million in 2026.
- The last three Cash & Equivalents figures came in at $41.5 million (Q1 2026), $17.0 million (Q4 2025), and $7.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 32.30 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 1.91 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 286.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 18.44 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 2.77 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 7.15 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.49 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 558.94 Mn |
| 10 | Canton Strategic Holdings | 699.97 Mn | 658.44 Mn | - | 41.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 41.53 Mn |
| Dec 31, 2025 | 17.03 Mn |
| Sep 30, 2025 | 7.61 Mn |
| Jun 30, 2025 | 2.24 Mn |
| Mar 31, 2025 | 1.08 Mn |
| Dec 31, 2024 | 3.56 Mn |
| Sep 30, 2024 | 4.77 Mn |
| Jun 30, 2024 | 7.90 Mn |
| Mar 31, 2024 | 8.43 Mn |
| Dec 31, 2023 | 10.94 Mn |
| Sep 30, 2023 | 2.69 Mn |
| Jun 30, 2023 | 3.90 Mn |
| Mar 31, 2023 | 3.57 Mn |
| Dec 31, 2022 | 6.51 Mn |
| Sep 30, 2022 | 7.60 Mn |
| Jun 30, 2022 | 9.48 Mn |
| Mar 31, 2022 | 11.12 Mn |
| Dec 31, 2021 | 4,356.00 |
| Sep 30, 2021 | 45,095.00 |
| Jun 30, 2021 | 29,271.00 |